Additional file 1: of The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness

Daniel Hormaechea‐Agulla(Baylor College of Medicine), Raúl M. Luque(Instituto de Salud Carlos III), Enrique Gómez‐Gómez(Instituto Maimónides de Investigación Biomédica de Córdoba), Rosa Ortega‐Salas(Instituto Maimónides de Investigación Biomédica de Córdoba), María Moreno(University of Sannio), Rafael Sánchez‐Sánchez(Instituto Maimónides de Investigación Biomédica de Córdoba), Manuel D. Gahete(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition), Steven J. Swanson(RPX (United States)), Juan M. Jiménez‐Vacas(Instituto de Salud Carlos III), Michael D. Culler(Ipsen (United States)), Julia Carrasco‐Valiente(Instituto Maimónides de Investigación Biomédica de Córdoba), Esther Rivero‐Cortés(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition), Alejandro Ibáñez‐Costa(Instituto de Salud Carlos III), André Sarmento‐Cabral(University of Illinois Chicago), Justo P. Castaño(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition), M.J. Requena(Instituto Maimónides de Investigación Biomédica de Córdoba), Natia Tsomaia(Ipsen (France)), J. Valero-Rosa(Instituto Maimónides de Investigación Biomédica de Córdoba)

Figshare

January 1, 2017

Cited by 0

|British Journal of Pharmacology|2021|488

|British Journal of Pharmacology|2023|390

|Nature|2004|295

|Pharmacological Reviews|2018|251

|Obesity Reviews|2005|121

Related Papers